Conditional survival of malignant melanoma in The Netherlands: 1994–2008
Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melan...
Gespeichert in:
Veröffentlicht in: | European journal of cancer (1990) 2014-02, Vol.50 (3), p.602-610 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 610 |
---|---|
container_issue | 3 |
container_start_page | 602 |
container_title | European journal of cancer (1990) |
container_volume | 50 |
creator | van der Leest, Robert J.T van Steenbergen, Liza N Hollestein, Loes M de Vries, Esther Nijsten, Tamar van Akkooi, Alexander C.J Janssen-Heijnen, Maryska L.G Coebergh, Jan-Willem W |
description | Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with >4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage. |
doi_str_mv | 10.1016/j.ejca.2013.10.019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492716009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S095980491300957X</els_id><sourcerecordid>1492716009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</originalsourceid><addsrcrecordid>eNp9kc1u1DAQgK0K1C6lL9ADygWJS5ax4yQ2QpWqFb-q4ECRuFmuPaEOid3ayUq98Q68YZ8ER7uA1AMnj0bfjGe-IeSUwpoCbV72a-yNXjOgVU6sgcoDsqKilSWImj0iK5C1LAVweUSepNQDQCs4HJIjxlnDalGvyMdN8NZNLng9FGmOW7fNQeiKUQ_uu9d-KkYctA-jLpwvLq-x-ITTNcacs-lVQaXk9z9_MQDxlDzu9JDwZP8ek69v31xu3pcXn9992JxflIZzOpUGhGm5ZdowKpgGFNUVQsepqayRWnLa4RJoJhjUkumG2bYBZjnVCE1dHZMXu743MdzOmCY1umRwyBNhmJOiXLKWNgAyo2yHmhhSitipm-hGHe8UBbU4VL1aHKrF4ZLLDnPRs33_-WpE-7fkj7QMPN8DOhk9dFF749I_TuQJsvTMvd5xmG1sHUaVjENv0LqIZlI2uP_Pcfag3AzOu_zjD7zD1Ic55qPlfVViCtSX5drLsWmVV6_bb9VvT22jKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492716009</pqid></control><display><type>article</type><title>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van der Leest, Robert J.T ; van Steenbergen, Liza N ; Hollestein, Loes M ; de Vries, Esther ; Nijsten, Tamar ; van Akkooi, Alexander C.J ; Janssen-Heijnen, Maryska L.G ; Coebergh, Jan-Willem W</creator><creatorcontrib>van der Leest, Robert J.T ; van Steenbergen, Liza N ; Hollestein, Loes M ; de Vries, Esther ; Nijsten, Tamar ; van Akkooi, Alexander C.J ; Janssen-Heijnen, Maryska L.G ; Coebergh, Jan-Willem W</creatorcontrib><description>Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with >4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2013.10.019</identifier><identifier>PMID: 24262585</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Conditional survival ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Medical sciences ; Melanoma ; Melanoma - mortality ; Melanoma - pathology ; Melanoma, Cutaneous Malignant ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Netherlands - epidemiology ; Pharmacology. Drug treatments ; Prognosis ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Survival Analysis ; Tumors ; Young Adult</subject><ispartof>European journal of cancer (1990), 2014-02, Vol.50 (3), p.602-610</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</citedby><cites>FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S095980491300957X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28149049$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24262585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Leest, Robert J.T</creatorcontrib><creatorcontrib>van Steenbergen, Liza N</creatorcontrib><creatorcontrib>Hollestein, Loes M</creatorcontrib><creatorcontrib>de Vries, Esther</creatorcontrib><creatorcontrib>Nijsten, Tamar</creatorcontrib><creatorcontrib>van Akkooi, Alexander C.J</creatorcontrib><creatorcontrib>Janssen-Heijnen, Maryska L.G</creatorcontrib><creatorcontrib>Coebergh, Jan-Willem W</creatorcontrib><title>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with >4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Conditional survival</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Melanoma - mortality</subject><subject>Melanoma - pathology</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Netherlands - epidemiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Survival Analysis</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAQgK0K1C6lL9ADygWJS5ax4yQ2QpWqFb-q4ECRuFmuPaEOid3ayUq98Q68YZ8ER7uA1AMnj0bfjGe-IeSUwpoCbV72a-yNXjOgVU6sgcoDsqKilSWImj0iK5C1LAVweUSepNQDQCs4HJIjxlnDalGvyMdN8NZNLng9FGmOW7fNQeiKUQ_uu9d-KkYctA-jLpwvLq-x-ITTNcacs-lVQaXk9z9_MQDxlDzu9JDwZP8ek69v31xu3pcXn9992JxflIZzOpUGhGm5ZdowKpgGFNUVQsepqayRWnLa4RJoJhjUkumG2bYBZjnVCE1dHZMXu743MdzOmCY1umRwyBNhmJOiXLKWNgAyo2yHmhhSitipm-hGHe8UBbU4VL1aHKrF4ZLLDnPRs33_-WpE-7fkj7QMPN8DOhk9dFF749I_TuQJsvTMvd5xmG1sHUaVjENv0LqIZlI2uP_Pcfag3AzOu_zjD7zD1Ic55qPlfVViCtSX5drLsWmVV6_bb9VvT22jKA</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>van der Leest, Robert J.T</creator><creator>van Steenbergen, Liza N</creator><creator>Hollestein, Loes M</creator><creator>de Vries, Esther</creator><creator>Nijsten, Tamar</creator><creator>van Akkooi, Alexander C.J</creator><creator>Janssen-Heijnen, Maryska L.G</creator><creator>Coebergh, Jan-Willem W</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140201</creationdate><title>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</title><author>van der Leest, Robert J.T ; van Steenbergen, Liza N ; Hollestein, Loes M ; de Vries, Esther ; Nijsten, Tamar ; van Akkooi, Alexander C.J ; Janssen-Heijnen, Maryska L.G ; Coebergh, Jan-Willem W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-c08c74d2ac2182a0e83be0f41c3dc9a941fedc9aa2820592a62d7602d41ae0653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Conditional survival</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Melanoma - mortality</topic><topic>Melanoma - pathology</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Netherlands - epidemiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Survival Analysis</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Leest, Robert J.T</creatorcontrib><creatorcontrib>van Steenbergen, Liza N</creatorcontrib><creatorcontrib>Hollestein, Loes M</creatorcontrib><creatorcontrib>de Vries, Esther</creatorcontrib><creatorcontrib>Nijsten, Tamar</creatorcontrib><creatorcontrib>van Akkooi, Alexander C.J</creatorcontrib><creatorcontrib>Janssen-Heijnen, Maryska L.G</creatorcontrib><creatorcontrib>Coebergh, Jan-Willem W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Leest, Robert J.T</au><au>van Steenbergen, Liza N</au><au>Hollestein, Loes M</au><au>de Vries, Esther</au><au>Nijsten, Tamar</au><au>van Akkooi, Alexander C.J</au><au>Janssen-Heijnen, Maryska L.G</au><au>Coebergh, Jan-Willem W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conditional survival of malignant melanoma in The Netherlands: 1994–2008</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>50</volume><issue>3</issue><spage>602</spage><epage>610</epage><pages>602-610</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Abstract Background Cutaneous malignant melanoma causes the majority of skin cancer related deaths and features increasing incidence and mortality rates in the Netherlands. Conditional survival analysis is performed on patients who survived the preceding year(s). Methods Patients with invasive melanoma, as recorded in the population-based Netherlands Cancer Registry, were included. To assess prognosis of melanoma survivors according to gender and Breslow thickness, conditional five-year relative survival was calculated for lymph node negative melanoma patients and conditional one-year relative survival was analysed for melanoma patients with and without nodal involvement. Findings Between 1994 and 2008, 40,050 patients developed a melanoma (stage I–III, of whom 6% with nodal involvement). Six to 8 years after diagnosis, survival of patients with a 1–2 mm (T2) thick melanoma equalised the general population. Conditional five-year relative survival for patients with >4 mm thick (T4) melanomas increased from about 60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in patients with thick melanomas and female patients with nodal involvement. Interpretation The prognosis for melanoma survivors improved with each additional year of survival after diagnosis, except for patients with a ⩽1 mm thick melanoma, who never had any excess mortality during follow-up. Conditional survival of melanoma was better amongst females, amongst those with lower Breslow thickness and nodal stage.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>24262585</pmid><doi>10.1016/j.ejca.2013.10.019</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0959-8049 |
ispartof | European journal of cancer (1990), 2014-02, Vol.50 (3), p.602-610 |
issn | 0959-8049 1879-0852 |
language | eng |
recordid | cdi_proquest_miscellaneous_1492716009 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Conditional survival Female Hematology, Oncology and Palliative Medicine Humans Male Medical sciences Melanoma Melanoma - mortality Melanoma - pathology Melanoma, Cutaneous Malignant Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Netherlands - epidemiology Pharmacology. Drug treatments Prognosis Skin Neoplasms - mortality Skin Neoplasms - pathology Survival Analysis Tumors Young Adult |
title | Conditional survival of malignant melanoma in The Netherlands: 1994–2008 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A01%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conditional%20survival%20of%20malignant%20melanoma%20in%20The%20Netherlands:%201994%E2%80%932008&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=van%20der%20Leest,%20Robert%20J.T&rft.date=2014-02-01&rft.volume=50&rft.issue=3&rft.spage=602&rft.epage=610&rft.pages=602-610&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2013.10.019&rft_dat=%3Cproquest_cross%3E1492716009%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1492716009&rft_id=info:pmid/24262585&rft_els_id=1_s2_0_S095980491300957X&rfr_iscdi=true |